Hematopoietic & Systemic ARS Countermeasure Therapeutics

Commercial sector

Hematopoietic & Systemic ARS Countermeasure Therapeutics

Developers of drugs, biologics, and cell therapies intended to prevent, mitigate, or treat acute radiation syndrome—primarily the hematopoietic sub-syndrome but also gastrointestinal, pulmonary, and cutaneous injury. Includes growth factors (G-CSF, GM-CSF, TPO agonists, IL-12), TLR agonists, immunomodulators, radioprotectant/radiomitigator small molecules and peptides, and cell/tissue therapies (MSCs, banked marrow, stem-cell-derived platelets).

Companies23
Commercial products63
Technology classes8
Countries4
Patents1,084

Profiled companies

Products
  • Partner Therapeutics, Inc. logo
    Partner Therapeutics, Inc.
    United States2
  • Humanetics Corporation logo
    Humanetics Corporation
    United States2
  • Synedgen logo
    Synedgen
    United States3
  • Valion Bio logo
    Valion Bio
    United States4
  • Bolder BioTechnology logo
    Bolder BioTechnology
    United States5
  • ChromoLogic logo
    ChromoLogic
    United States2

+ 17 more

← Back to what’s inside this report